Tillotts Pharma and TVM Capital Life Science form Mage Biologics to develop oral antibody therapy for ulcerative colitis
TVM Capital Life Science, a leading international venture capital firm focused on investments in life sciences innovation, together with specialty pharma company, Tillotts Pharma, will jointly invest up to US$28 million in the newly formed U.S.-based biotechnology company, Mage Biologics. TVM will invest with its fund TVM Life Science Innovation II SCSp (TVM LSI II) […]
